A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication
This study has been completed.
Sponsor:
AstraZeneca
Collaborators:
Dr. Marie-Therese Lussier
Dr. Claude Richard
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00879736
First received: April 8, 2009
Last updated: August 19, 2011
Last verified: October 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is being carried out to see if patients make the lifestyle changes or take their medication as instructed by their doctor during their visit as a result of the T.H.T. patient-education training. Proper information exchange between doctors and patients is an important part of quality health care. Although many patients would like more information, they often do not ask for it directly during doctor-patient visits. The patient-training in this study specifically aims at improving patient participation during medical appointments by building communication skills such as requests for information and sharing health concerns with the doctor.
| Condition | Intervention |
|---|---|
|
Doctor-patient Communication Improvement |
Behavioral: THT PACE Training Other: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Prevention |
| Official Title: | A Multi-centre, Randomised Trial in Ontario to Evaluate the Efficacy of Talking Health Together T.M. (T.H.T. in Practice), a Communication Education Intervention for Primary Care Patients With Chronic Disease. |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- To evaluate the impact, compared to Usual Care, of training interventions on patients with chronic disease on patient participation in primary care encounters assessed after intervention. [ Time Frame: once ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- physician satisfaction and sense of partnership with the doctor-patient encounter; [ Designated as safety issue: No ]
- patient perception of quality of doctor-patient communication and relationship and patient confidence in own ability to communicate effectively with their doctor; [ Time Frame: Twice ] [ Designated as safety issue: No ]
- patient perception of the management of their chronic disease(s); and patient recall of discussions of lifestyle recommendations and chronic disease medications discussed during the encounter. [ Time Frame: Twice ] [ Designated as safety issue: No ]
| Enrollment: | 322 |
| Study Start Date: | March 2009 |
| Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: THT PACE eLearning module
The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
|
Behavioral: THT PACE Training
Patient training
|
|
Active Comparator: THT PACE eLearning module & nurse-led workshop training
THT PACE eLearning and then nurse-led workshop for training on PACE methodology
|
Behavioral: THT PACE Training
Patient training
|
|
Placebo Comparator: Usual care
Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
|
Other: placebo |
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female, aged 40 years of age or greater
- Clinical documentation of diagnosis not to target of at least one of the following: Type II Diabetes Mellitus, Hypertension or Hypercholesterolemia
- Receive a prescribed medication for the chronic disease for which they were included in the study
Exclusion Criteria:
- Patients in active phase of cancer treatment (i.e. chemotherapy or radiotherapy at time of study).
- Inability to carry out the encounter with their physician in English without need of assistance
- Uncomfortable using a computer for routine activities such as regular access to the web and e-mail.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00879736
Locations
| Canada, Ontario | |
| Research Site | |
| Burlington, Ontario, Canada | |
| Research Site | |
| Hamilton, Ontario, Canada | |
| Research Site | |
| Kitchener-Waterloo, Ontario, Canada | |
| Research Site | |
| Mississauga, Ontario, Canada | |
| Research Site | |
| Oakville, Ontario, Canada | |
Sponsors and Collaborators
AstraZeneca
Dr. Marie-Therese Lussier
Dr. Claude Richard
Investigators
| Principal Investigator: | Dr. Marie-Thérèse Lussier, MD, BSc., MSc., FCMFC | Université de Montréal |
More Information
No publications provided
| Responsible Party: | AstraZeneca, Astrazeneca |
| ClinicalTrials.gov Identifier: | NCT00879736 History of Changes |
| Other Study ID Numbers: | THT in practice |
| Study First Received: | April 8, 2009 |
| Last Updated: | August 19, 2011 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by AstraZeneca:
|
Doctor-patient communication Encounters Patient education training |
ClinicalTrials.gov processed this record on May 16, 2013